DNA Earnings & Financial Statements
Ginkgo Bioworks Holdings, Inc.
$11.15
-$0.32(-2.79%)
64
Overall
60
Value
91
Tech
42
Quality
Market Cap
$798.46M
Volume
1.78M
52W Range
$5.37 - $17.58
Target Price
$7.00
DNA earnings and financial statements: Ginkgo Bioworks Holdings, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DNA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $170.16M | $227.04M | $251.46M | $477.71M | $313.84M |
| Cost of revenue | $46.97M | $44.55M | $54.01M | $204.22M | $109.67M |
| Operating income | -$315.28M | -$559.76M | -$864.41M | -$2.21B | -$1.83B |
| EBITDA | -$224.53M | -$456.30M | -$794.03M | -$2.05B | -$1.81B |
| Net income | -$312.76M | -$547.03M | -$892.87M | -$2.10B | -$1.83B |
| EPS (diluted) | $-5.64 | $-10.54 | $-18.40 | $-50.00 | $-55.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B |
| Total liabilities | $611.11M | $661.39M | $568.19M | $803.04M | $503.61M |
| Shareholders’ equity | $508.59M | $716.06M | $1.10B | $1.75B | $1.51B |
| Cash and equivalents | $167.20M | $561.57M | $944.07M | $1.32B | $1.55B |
| Long-term debt | $417.08M | $438.77M | $221.84M | $413.26M | $22.28M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$171.06M | -$319.58M | -$295.50M | -$252.20M | -$253.82M |
| Capital expenditure | -$7.09M | -$61.89M | -$40.80M | -$52.27M | -$56.52M |
| Free cash flow | -$178.72M | -$382.13M | -$336.30M | -$304.47M | -$310.34M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DNA | $11.15 | -2.8% | 1.78M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ginkgo Bioworks Holdings, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW